<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825655</url>
  </required_header>
  <id_info>
    <org_study_id>IIS2012-003</org_study_id>
    <nct_id>NCT01825655</nct_id>
  </id_info>
  <brief_title>Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching</brief_title>
  <official_title>Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine if long acting antihistamine like zyrtec can help
      with itching induced by opioid pain medications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Itch score</measure>
    <time_frame>3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Itch score will be used to analyze our primary outcome. The subjects will have an itch score at baseline and compared to itch score at 3hrs post intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Cetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zyrtec 10mg, oral, one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one pill, one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <arm_group_label>Cetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo or sugar pill</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 6-18yrs on opioids who develop pruritus and are willing to participate
             in the study

        Exclusion Criteria:

          -  Children with history of chronic urticaria

          -  Children with other chronic pruritic condition like eczema, contact dermatitis,
             psoriasis

          -  Children with known hypersensitivity to cetirizine

          -  Children on second generation antihistamine 1 week prior to the study recruitment

          -  Children who are unwilling or unable to swallow the capsule

          -  Children with chronic liver or kidney disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santhosh Kumar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santhosh Kumar, MD</last_name>
    <phone>804-628-1605</phone>
    <email>skumar@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
